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Dear Editor,
We have read with great interest the review article by 
Marinelli et al. (1) entitled “Gamma-hydroxybutyrate abuse: 
pharmacology and poisoning and withdrawal management”. 
This review focuses on updated knowledge about GHB 
pharmacokinetics and pharmacodynamics, acute poisoning, 
and clinical features of GHB withdrawal syndrome, its 
diagnosis, and medical treatment.
In addition, the authors give special emphasis to “new 
frontiers in GHB” taking into consideration the emerging 
role of -butyrolactone (GBL) and 1,4-butanediol (1,4-BD).
While we agree with the considerations raised by 
Marinelli et al. (1), we wish to further discuss the role of 
GBL, which has completely replaced the use of GHB as 
white powder in recreational settings but also as a date rape 
drug (2–4). Besides GBL, GHB can be obtained in its 
sodium salt form (sodium oxybate), which is currently 
marketed for the treatment of alcohol withdrawal syndrome 
(Alcover?) and narcolepsy with cataplexy (Xyrem?) (5, 6).
Marinelli et al. (1) stated that 1 mL of pure GBL contains 
about 1.6 g of GHB, but GBL significantly varies in the degree 
of purity. Analysing 30 illicit preparations generally sold as 
“G”, Busardò et al. (2) highlighted the presence of GBL in all 
of them at a mean concentration of 760.7±91.46 mg/mL and 
a wide range of 588.5–899.3 mg/mL. The consequence of this 
variability is that users cannot base the dosage on volume and 
therefore run a higher risk of overdose than with GHB.
Presently, the main concern associated with GBL abuse 
is the lack of data about its actual distribution and its rapid 
conversion into GHB after ingestion. Moreover, in cases 
of acute poisoning and fatalities only GHB is looked for in 
biological samples and symptoms are univocally attributed 
to GHB (2, 7, 8). This calls for highly sensitive analytical 
methods that would be able to detect not only GHB but also 
its precursors (and metabolites) in conventional and non-
conventional biological matrices. Speaking of the latter, 
hair seems to have a great potential for this type of analysis 
(9). Considering GBL’s availability in certain contexts such 
as in homosexual clubs and chemsex parties, it is 
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fundamental to develop analytical strategies able to detect 
not only GHB/GBL but also other associated classes of 
substances, mainly synthetic cathinones such as mephedrone 
(10, 11).
In conclusion, we firmly believe that GBL currently 
represents a growing public health issue, since the substance 
is relatively cheaper and easier to obtain than GHB (12, 
13). Improvement and implementation of laws and policies 
to place GBL under control are needed to limit its 
distribution, considerable abuse, and associated health and 
dependence risks.
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